FDA will review Enflonsia's ability to protect high-risk children under 2 years of age during their second RSV season.
Inhalation Solution would become the first inhaled option designed to treat idiopathic pulmonary fibrosis (IPF).
Updated formulas from Pfizer, Moderna, and Novavax target the circulating XFG variant for older adults and high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results